rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2022-505-518rsp-3215Research ArticleПЕРЕДОВАЯLEADING ARTICLEПерспективы ингибиции интерлейкина-6 при ревматоидном артрите: олокизумаб (новые моноклональные антитела к ИЛ-6)The prospects of interleukin-6 inhibition in rheumatoid arthritis: Olokizumab (novel monoclonal antibodies to IL-6)https://orcid.org/0000-0002-1598-8360НасоновЕ. Л.NasonovE. L.

11552, Москва, Каширское шоссе, 34а; 119991, Москва, ул. Трубецкая, 8, стр. 2

115522, Moscow, Kashirskoye Highway, 34A; 119991, Moscow, Trubetskaya str., 8, building 2 

nasonov@irramn.ruhttps://orcid.org/0000-0002-9872-5282ФайстЕ.FeistE.

39245, Гоммерн, Софи-в.- Беттихер-Штрассе, 1

39245, Gommern, Sophie-v.- Boetticher-Straße, 1

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияV.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University of the Ministry of Health Care of Russian Federation (Sechenov University)Russian FederationОтделение ревматологии Клиники Гелиос Фогельсанг-Гоммерн, партнер по сотрудничеству Магдебургского университета имени Отто фон ГерикеГерманияDepartment of Rheumatology, Helios Clinic VogelsangGommern, cooperation partner of the Otto-vonGuericke University MagdeburgGermany202210112022605505518Copyright © Насонов Е.Л., Файст Е., 20222022Насонов Е.Л., Файст Е.Nasonov E.L., Feist E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3215

Ревматоидный артрит (РА) – хроническое иммуновоспалительное ревматическое заболевание (ИВРЗ), проявляющееся прогрессирующей деструкцией суставов, системным воспалением внутренних органов и широким спектром коморбидных заболеваний, связанных с хроническим воспалением. В спектре цитокинов, принимающих участие в патогенезе РА и других ИВРЗ, большое внимание уделяется роли интерлейкина (ИЛ) 6. Внедрение в клиническую практику моноклональных антител (мАТ) – тоцилизумаба (ТЦЗ), а затем сарилумаба (САР), блокирующих клеточные эффекты этого цитокина, относится к числу крупнейших достижений в лечении ИВРЗ в начале XXI века. Особое внимание привлекают гуманизированные мАТ к ИЛ-6 – олокизумаб (ОКЗ), разработанные Российской компанией «Р-ФАРМ» в рамках лицензионного соглашения с UCB Pharma. В обзоре рассматриваются новые данные, касающиеся эффективности и безопасности ОКЗ при РА и перспективы применения ОКЗ в ревматологии.

Rheumatoid arthritis (RA) is a chronic immune-mediated rheumatic diseases (IMRDs) manifested with progressive destruction of joints, systemic inflammation of visceral organs and a wide range of co-morbidities associated with chronic inflammation. Among the cytokines involved in the pathogenesis of RA and certain other IMRDs, the role of interleukin (IL) 6 is of special interest. The introduction of mAbs tocilizumab (TCZ) and later sarilumab (SAR), both blocking the receptor of this cytokine, into clinical practice was an important achievement in the treatment of IIRDs at the beginning of the 21st century. As a novel approach in the treatment of RA, the humanized mAb against IL-6 olokizumab (OKZ) is in development by the Russian company R-PHARM under the license agreement with UCB Pharma. The review examines new data on efficacy and safety of OKZ in RA and the prospects of its use in rheumatology

ревматоидный артритгенно-инженерные биологические препаратыинтерлейкин-6ингибиторы интерлейкина-6тоцилизумаболокизумабrheumatoid arthritisbiological agentsinterleukin-6interleukin-6 inhibitorstocilizumabolokizumabReferencesSmolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–2038. doi: 10.1016/S0140-6736(16)30173-8Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–2038. doi: 10.1016/S0140-6736(16)30173-8Firestein GS, McInnes IB. Immunopathogenesis of Rheumatoid Arthritis. Immunity. 2017;46(2):183–196. doi: 10.1016/j.immuni. 2017.02.006Firestein GS, McInnes IB. Immunopathogenesis of Rheumatoid Arthritis. Immunity. 2017;46(2):183–196. doi: 10.1016/j.immuni. 2017.02.006McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017;389(10086):2328–2337. doi: 10.1016/S0140-6736(17)31472-1McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017;389(10086):2328–2337. doi: 10.1016/S0140-6736(17)31472-1Burmester GR, Bijlsma JWJ, Cutolo M, McInnes IB. Managing rheumatic and musculoskeletal diseases – past, present and future. Nat Rev Rheumatol. 2017;13(7):443–448. doi: 10.1038/nrrheum. 2017.95Burmester GR, Bijlsma JWJ, Cutolo M, McInnes IB. Managing rheumatic and musculoskeletal diseases – past, present and future. Nat Rev Rheumatol. 2017;13(7):443–448. doi: 10.1038/nrrheum. 2017.95Насонов ЕЛ. Фармакотерапия ревматоидного артрита: новая стратегия, новые мишени. Научно-практическая ревматология. 2017;55(4):409–419.Nasonov EL. Pharmacotherapy for rheumatoid arthritis: new strategy, new targets. Nauchno-Prakticheskaya Rev matologia = Rheumatology Science and Practice. 2017;55(4):409– 419 (In Russ.) doi: 10.14412/1995-4484-2017-409-419Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, et al.; T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69(4):631–637. doi: 10.1136/ard.2009.123919.Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, et al.; T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69(4):631–637. doi: 10.1136/ard.2009.123919.Mian A, Ibrahim F, Scott DL. A systematic review of guidelines for managing rheumatoid arthritis. BMC Rheumatol. 2019;3:42. doi: 10.1186/s41927-019-0090-7Mian A, Ibrahim F, Scott DL. A systematic review of guidelines for managing rheumatoid arthritis. BMC Rheumatol. 2019;3:42. doi: 10.1186/s41927-019-0090-7Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. Lancet. 2017;389:2338–2348. doi: 10.1016/S0140-6736(17) 31491-5Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. Lancet. 2017;389:2338–2348. doi: 10.1016/S0140-6736(17) 31491-5Winthrop KL, Weinblatt ME, Bathon J, Burmester GR, Mease PJ, et al. Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019. Ann Rheum Dis. 2020;79(1):88–93. doi: 10.1136/annrheumdis-2019-216151Winthrop KL, Weinblatt ME, Bathon J, Burmester GR, Mease PJ, et al. Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019. Ann Rheum Dis. 2020;79(1):88–93. doi: 10.1136/annrheumdis-2019-216151Schett G, McInnes IB, Neurath MF. Reframing Immune-Mediated Inflammatory Diseases through Signature Cytokine Hubs. N Engl J Med. 2021;385(7):628–639. doi: 10.1056/NEJMra1909094Schett G, McInnes IB, Neurath MF. Reframing Immune-Mediated Inflammatory Diseases through Signature Cytokine Hubs. N Engl J Med. 2021;385(7):628–639. doi: 10.1056/NEJMra1909094Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015;16(5):448–457. doi: 10.1038/ni.3153Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015;16(5):448–457. doi: 10.1038/ni.3153Choy, E.H., De Benedetti, F., Takeuchi, T. et al. Translating IL-6 biology into effective treatments. Nat Rev Rheumatol. 2020; 16, 335–345. https://doi.org/10.1038/s41584-020-0419-zChoy, E.H., De Benedetti, F., Takeuchi, T. et al. Translating IL-6 biology into effective treatments. Nat Rev Rheumatol. 2020; 16, 335–345. https://doi.org/10.1038/s41584-020-0419-zKang S, Tanaka T, Narazaki M, Kishimoto T. Targeting Interleukin-6 Signaling in Clinic. Immunity. 2019;50(4):1007–1023. doi: 10.1016/j.immuni.2019.03.026Kang S, Tanaka T, Narazaki M, Kishimoto T. Targeting Interleukin-6 Signaling in Clinic. Immunity. 2019;50(4):1007–1023. doi: 10.1016/j.immuni.2019.03.026Kishimoto T, Kang S. IL-6 Revisited: From Rheumatoid Arthritis to CAR T Cell Therapy and COVID-19. Annu Rev Immunol. 2022;40:323–348. doi: 10.1146/annurev-immunol-101220-023458Kishimoto T, Kang S. IL-6 Revisited: From Rheumatoid Arthritis to CAR T Cell Therapy and COVID-19. Annu Rev Immunol. 2022;40:323–348. doi: 10.1146/annurev-immunol-101220-023458Насонов ЕЛ, Лила АМ. Ингибиция интерлейкина-6 при иммуновоспалительных ревматических заболеваниях: достижения, перспективы и надежды. Научно-практическая ревматология. 2017;55(6):590–599.Nasonov EL, Lila AM. Inhibition of interleukin 6 in immune inflammatory rheumatic diseases: achievements, prospects, and hopes. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(6):590–599 (In Russ.) doi: 10.14412/1995-4484-2017-590-599Насонов Е.Л. Применение тоцилизумаба при ревматоидном артрите: новые данные. Научно-практическая ревматология. 2011;49(6):46–56Nasonov EL. Use of tocilizumab for rheumatoid arthritis: new evidence. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2011; 49(6):46–56 (In Russ.).Scott LJ. Tocilizumab: A Review in Rheumatoid Arthritis. Drugs. 2017;77(17):1865-1879. doi: 10.1007/s40265-017-0829-7.Scott LJ. Tocilizumab: A Review in Rheumatoid Arthritis. Drugs. 2017;77(17):1865-1879. doi: 10.1007/s40265-017-0829-7.Насонов ЕЛ, Лила АМ. Эффективность и безопасность сарилумаба (полностью человеческие моноклональные антитела к рецептору интерлейкина-6) при ревматоидном артрите: новые данные. Научно-практическая ревматология. 2019; 57(5):564–577Nasonov EL, Lila AM. The efficacy and safety of sarilumab, fully human monoclonal antibodies against interleukin-6 receptor, in rheumatoid arthritis: new evidence. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(5):564–577 (In Russ.). doi: org/10.14412/1995- 4484-2019-564-57Raimondo MG, Biggioggero M, Crotti C, Becciolini A, Favalli EG. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. Drug Des Devel Ther. 2017;11:1593–1603. doi: 10.2147/ DDDT.S100302Raimondo MG, Biggioggero M, Crotti C, Becciolini A, Favalli EG. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. Drug Des Devel Ther. 2017;11:1593–1603. doi: 10.2147/ DDDT.S100302Pelechas E, Voulgari PV, Drosos AA. Sirukumab: a promising therapy for rheumatoid arthritis. Expert Opin Biol Ther. 2017;17(6):755–763. doi: 10.1080/14712598.2017.1315099Pelechas E, Voulgari PV, Drosos AA. Sirukumab: a promising therapy for rheumatoid arthritis. Expert Opin Biol Ther. 2017;17(6):755–763. doi: 10.1080/14712598.2017.1315099Tanaka Y, Martin Mola E. IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab. Ann Rheum Dis. 2014;73(9):1595–1597. doi: 10.1136/ annrheumdis-2013-205002Tanaka Y, Martin Mola E. IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab. Ann Rheum Dis. 2014;73(9):1595–1597. doi: 10.1136/ annrheumdis-2013-205002Serio I, Tovoli F. Rheumatoid arthritis: new monoclonal antibodies. Drugs Today (Barc). 2018;54(3):219–230. doi: 10.1358/ dot.2018.54.3.2788019Serio I, Tovoli F. Rheumatoid arthritis: new monoclonal antibodies. Drugs Today (Barc). 2018;54(3):219–230. doi: 10.1358/ dot.2018.54.3.2788019Shaw S, Bourne T, Meier C, Carrington B, Gelinas R, et al. Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling. MAbs. 2014;6 (3):774–82. doi: 10.4161/mabs.28612Shaw S, Bourne T, Meier C, Carrington B, Gelinas R, et al. Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling. MAbs. 2014;6 (3):774–82. doi: 10.4161/mabs.28612Favalli EG. Understanding the Role of Interleukin-6 (IL-6) in the Joint and Beyond: A Comprehensive Review of IL-6 Inhibition for the Management of Rheumatoid Arthritis. Rheumatol Ther. 2020;7(3):473–516. doi: 10.1007/s40744-020-00219-2Favalli EG. Understanding the Role of Interleukin-6 (IL-6) in the Joint and Beyond: A Comprehensive Review of IL-6 Inhibition for the Management of Rheumatoid Arthritis. Rheumatol Ther. 2020;7(3):473–516. doi: 10.1007/s40744-020-00219-2Narazaki M, Kishimoto T. Current status and prospects of IL6-targeting therapy. Exp Rev Clin Pharm. 2022;15 (5):575–592. doi: 10.1080/17512433.2022.2097905Narazaki M, Kishimoto T. Current status and prospects of IL6-targeting therapy. Exp Rev Clin Pharm. 2022;15 (5):575–592. doi: 10.1080/17512433.2022.2097905Jarlborg M, Gabay C. Systemic effects of IL-6 blockade in rheumatoid arthritis beyond the joints. Cytokine. 2022;149. doi: org/10.1016/j.cyto.2021.155742Jarlborg M, Gabay C. Systemic effects of IL-6 blockade in rheumatoid arthritis beyond the joints. Cytokine. 2022;149. doi: org/10.1016/j.cyto.2021.155742Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, et al.; OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371(9617):987–997. doi: 10.1016/ S0140-6736(08)60453-5Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, et al.; OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371(9617):987–997. doi: 10.1016/ S0140-6736(08)60453-5Kremer JM, Blanco R, Brzosko M, Burgos-Vargas R, Halland AM, Vernon E, Ambs P, Fleischmann R. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum. 2011;63(3):609–621. doi: 10.1002/art.30158Kremer JM, Blanco R, Brzosko M, Burgos-Vargas R, Halland AM, Vernon E, Ambs P, Fleischmann R. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum. 2011;63(3):609–621. doi: 10.1002/art.30158Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58(10):2968–2980. doi: 10.1002/art.23940Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58(10):2968–2980. doi: 10.1002/art.23940Yazici Y, Curtis JR, Ince A, Baraf H, Malamet RL, Teng LL, Kavanaugh A. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Ann Rheum Dis. 2012;71(2):198–205. doi: 10.1136/ ard.2010.148700Yazici Y, Curtis JR, Ince A, Baraf H, Malamet RL, Teng LL, Kavanaugh A. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Ann Rheum Dis. 2012;71(2):198–205. doi: 10.1136/ ard.2010.148700Burmester GR, Rubbert-Roth A, Cantagrel A, Hall S, Leszczynski P, et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional diseasemodifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis. 2014;73(1):69–74. doi: 10.1136/annrheumdis-2013-203523Burmester GR, Rubbert-Roth A, Cantagrel A, Hall S, Leszczynski P, et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional diseasemodifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis. 2014;73(1):69–74. doi: 10.1136/annrheumdis-2013-203523Kivitz A, Olech E, Borofsky M, Zazueta BM, Navarro-Sarabia F, et al. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014;66(11):1653– 1661. doi: 10.1002/acr.22384Kivitz A, Olech E, Borofsky M, Zazueta BM, Navarro-Sarabia F, et al. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014;66(11):1653– 1661. doi: 10.1002/acr.22384Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to antitumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67(11):1516–1523. doi: 10.1136/ard.2008.092932Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to antitumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67(11):1516–1523. doi: 10.1136/ard.2008.092932Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, et al.; ADACTA Study Investigators. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet. 2013;381(9877):1541–1550. doi: 10.1016/S0140- 6736(13)60250-0Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, et al.; ADACTA Study Investigators. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet. 2013;381(9877):1541–1550. doi: 10.1016/S0140- 6736(13)60250-0Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009;19(1):12–19. doi: 10.1007/s10165-008- 0125-1Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009;19(1):12–19. doi: 10.1007/s10165-008- 0125-1Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69(1):88– 96. doi: 10.1136/ard.2008.105197Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69(1):88– 96. doi: 10.1136/ard.2008.105197Bijlsma JWJ, Welsing PMJ, Woodworth TG, Middelink LM, Pethö-Schramm A, et al. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial. Lancet. 2016;388(10042):343–355. doi: 10.1016/S0140- 6736(16)30363-4.Bijlsma JWJ, Welsing PMJ, Woodworth TG, Middelink LM, Pethö-Schramm A, et al. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial. Lancet. 2016;388(10042):343–355. doi: 10.1016/S0140- 6736(16)30363-4.Burmester GR, Rigby WF, van Vollenhoven RF, Kay J, Rubbert-Roth A, et al. Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial. Ann Rheum Dis. 2017;76(7):1279–1284. doi: 10.1136/annrheumdis-2016-210561.Burmester GR, Rigby WF, van Vollenhoven RF, Kay J, RubbertRoth A, et al. Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial. Ann Rheum Dis. 2017;76(7):1279–1284. doi: 10.1136/ annrheumdis-2016-210561.Genovese MC, Fleischmann R, Kivitz AJ, Rell-Bakalarska M, Martincova R, et al.. Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study. Arthritis Rheumatol. 2015;67(6):1424–1437. doi: 10.1002/art.39093Genovese MC, Fleischmann R, Kivitz AJ, Rell-Bakalarska M, Martincova R, et al.. Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study. Arthritis Rheumatol. 2015;67(6):1424–1437. doi: 10.1002/art.39093Tanaka Y, Wada K, Takahashi Y, Hagino O, van Hoogstraten H, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan. Arthritis Res Ther. 2019;21(1):79. doi: 10.1186/s13075-019-1856-4Tanaka Y, Wada K, Takahashi Y, Hagino O, van Hoogstraten H, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan. Arthritis Res Ther. 2019;21(1):79. doi: 10.1186/s13075-019-1856-4Fleischmann R, van Adelsberg J, Lin Y, Castelar-Pinheiro GD, Brzezicki J, et al. Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors. Arthritis Rheumatol. 2017;69(2):277–290. doi: 10.1002/ art.39944Fleischmann R, van Adelsberg J, Lin Y, Castelar-Pinheiro GD, Brzezicki J, et al. Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors. Arthritis Rheumatol. 2017;69(2):277–290. doi: 10.1002/ art.39944Burmester GR, Lin Y, Patel R, van Adelsberg J, Mangan EK, et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallelgroup phase III trial. Ann Rheum Dis. 2017;76(5):840–847. doi: 10.1136/annrheumdis-2016-210310Burmester GR, Lin Y, Patel R, van Adelsberg J, Mangan EK, et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallelgroup phase III trial. Ann Rheum Dis. 2017;76(5):840–847. doi: 10.1136/annrheumdis-2016-210310Nasonov E, Fatenejad S, Feist E, Ivanova M, Korneva E, et al. Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study. Ann Rheum Dis. 2022;81(4):469–479. doi: 10.1136/annrheumdis-2021-219876Nasonov E, Fatenejad S, Feist E, Ivanova M, Korneva E, et al. Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study. Ann Rheum Dis. 2022;81(4):469–479. doi: 10.1136/annrheumdis-2021-219876Smolen JS, Feist E, Fatenejad S, Grishin SA, Korneva EV, Nasonov EL, et al. ; CREDO2 Group. Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 2022;387(8):715–726. doi: 10.1056/NEJMoa2201302Smolen JS, Feist E, Fatenejad S, Grishin SA, Korneva EV, Nasonov EL, et al. ; CREDO2 Group. Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 2022;387(8):715–726. doi: 10.1056/NEJMoa2201302Feist E, Fatenejad S, Grishin S, Korneva E, Luggen ME, Nasonov E, et al. Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study. Ann Rheum Dis. 2022 Sep 15:annrheumdis-2022-222630. doi: 10.1136/ard-2022-222630Feist E, Fatenejad S, Grishin S, Korneva E, Luggen ME, Nasonov E, et al. Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study. Ann Rheum Dis. 2022 Sep 15:annrheumdis-2022-222630. doi: 10.1136/ard-2022-222630Genovese MC, Fleischmann R, Furst D, Janssen N, Carter J, et al. Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. Ann Rheum Dis. 2014;73(9):1607–1615. doi: 10.1136/annrheumdis-2013-204760Genovese MC, Fleischmann R, Furst D, Janssen N, Carter J, et al. Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. Ann Rheum Dis. 2014;73(9):1607–1615. doi: 10.1136/annrheumdis-2013-204760Takeuchi T, Tanaka Y, Yamanaka H, Amano K, Nagamine R, et al. Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial. Mod Rheumatol. 2016;26(1):15–23. doi: 10.3109/14397595.2015.1074648Takeuchi T, Tanaka Y, Yamanaka H, Amano K, Nagamine R, et al. Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial. Mod Rheumatol. 2016;26(1):15–23. doi: 10.3109/14397595.2015.1074648Administration USFD (2020). New Drug Application (NDA): 009768, Original Approvals or Tentative Approvals. Silver Spring, MD: US Food and Drug Administration. Available at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=009768 (Accessed May 3, 2020).Administration USFD (2020). New Drug Application (NDA): 009768, Original Approvals or Tentative Approvals. Silver Spring, MD: US Food and Drug Administration. Available at: https://www. accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview. process&ApplNo=009768 (Accessed May 3, 2020).Мазуров ВИ, Зоткин ЕГ, Гайдукова ИЗ, Иливанова ЕП, Кропотина ТВ, и соавт. Эффективность и безопасность применения левилимаба в комбинации с метотрексатом у пациентов с ревматоидным артритом: результаты II фазы исследования AURORA. Научно-практическая ревматология. 2021;59(2): 141–151.Mazurov VI, Zotkin EG, Gaydukova IZ, Ilivanova EP, Kropotina TV, et al. Efficacy and safety of levilimab in combination with methotrexate in subjects with rheumatoid arthritis: Results of phase II AURORA study. Nauchno-Prakticheskaya Rev matologia = Rheumatology Science and Practice. 2021;59(2):141–151 (In Russ.). doi:10.47360/1995-4484-2021-141-151Takeuchi T, Thorne C, Karpouzas G, Sheng S, Xu W, Rao R, Fei K, Hsu B, Tak PP. Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study. Ann Rheum Dis. 2017;76(12):2001–2008. doi: 10.1136/annrheumdis-2017-211328Takeuchi T, Thorne C, Karpouzas G, Sheng S, Xu W, Rao R, Fei K, Hsu B, Tak PP. Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study. Ann Rheum Dis. 2017;76(12):2001–2008. doi: 10.1136/annrheumdis-2017-211328Aletaha D, Bingham CO 3rd, Tanaka Y, Agarwal P, Kurrasch R, et al. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study. Lancet. 2017;389(10075):1206–1217. doi: 10.1016/S0140-6736(17)30401-4Aletaha D, Bingham CO 3rd, Tanaka Y, Agarwal P, Kurrasch R, et al. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study. Lancet. 2017;389(10075):1206–1217. doi: 10.1016/S0140-6736(17)30401-4Aletaha D, Kerscbaumer A, Kastrati K, Dejaco C, Dougados M, et al. Consensus statement on blocking interleukin-6 receptor and interleukin-6 in infkammatory conditions: an update. Ann Rheum Dis 2022. doi:10.1136/annrheumdis-2022-222784Aletaha D, Kerscbaumer A, Kastrati K, Dejaco C, Dougados M, et al. Consensus statement on blocking interleukin-6 receptor and interleukin-6 in infkammatory conditions: an update. Ann Rheum Dis 2022. doi:10.1136/annrheumdis-2022-222784Kastrati K, Aletaha D, Burmester GR, Chwala E, Dejaco C et al. A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immunemediated inflammatory diseases. RMD Open. 2022;8:e002359. doi: 10.1136/rmdopen-2022-002359Kastrati K, Aletaha D, Burmester GR, Chwala E, Dejaco C et al. A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immunemediated inflammatory diseases. RMD Open. 2022;8:e002359. doi: 10.1136/rmdopen-2022-002359Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological diseasemodifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685–699. doi: 10.1136/annrheumdis-2019-216655Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological diseasemodifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685–699. doi: 10.1136/annrheumdis-2019-216655Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2021;73(7):924–939. doi: 10.1002/acr.24596Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2021;73(7):924–939. doi: 10.1002/acr.24596Hetland ML, Haavardsholm EA, Rudin A, Nordström D, Nurmohamed M, et al.; NORD-STAR study group. Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial. BMJ. 2020;371:m4328. doi: 10.1136/bmj.m4328Hetland ML, Haavardsholm EA, Rudin A, Nordström D, Nurmohamed M, et al.; NORD-STAR study group. Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial. BMJ. 2020;371:m4328. doi: 10.1136/bmj.m4328Humby F, Durez P, Buch MH, Lewis MJ, Rizvet H et al. Rituximab versus tocilizumab in anti-TNF inadequate Responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet. 2021; 397(10271):305–317. doi: 10.1016/S0140-6736(20)32341-2Humby F, Durez P, Buch MH, Lewis MJ, Rizvet H et al. Rituximab versus tocilizumab in anti-TNF inadequate Responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet. 2021; 397(10271):305–317. doi: 10.1016/S0140-6736(20)32341-2Pappas DA, St John G, Etzel CJ, Fiore S, Blachley T, et al. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study. Ann Rheum Dis. 2021;80(1): 96–102. doi: 10.1136/annrheumdis-2020-217209Pappas DA, St John G, Etzel CJ, Fiore S, Blachley T, et al. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study. Ann Rheum Dis. 2021;80(1): 96–102. doi: 10.1136/annrheumdis-2020-217209Gottenberg JE, Morel J, Perrodeau E, Bardin T, Combe B, et al.; French Society of Rheumatology and the investigators participating in AIR, ORA, and REGATE registries. Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study. BMJ. 2019;364:l67. doi: 10.1136/bmj.l67Gottenberg JE, Morel J, Perrodeau E, Bardin T, Combe B, et al.; French Society of Rheumatology and the investigators participating in AIR, ORA, and REGATE registries. Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study. BMJ. 2019;364:l67. doi: 10.1136/bmj.l67Dougados M, Kissel K, Conaghan PG, Mola EM, Schett G, et al. Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis. 2014;73(5):803–809. doi: 10.1136/annrheumdis-2013-204761Dougados M, Kissel K, Conaghan PG, Mola EM, Schett G, et al. Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis. 2014;73(5):803–809. doi: 10.1136/annrheumdis-2013-204761Burmester GR, Rigby WF, van Vollenhoven RF, Kay J, RubbertRoth A, Kelman A, Dimonaco S, Mitchell N. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rheum Dis. 2016;75(6):1081–1091. doi: 10.1136/ annrheumdis-2015-207628Burmester GR, Rigby WF, van Vollenhoven RF, Kay J, RubbertRoth A, Kelman A, Dimonaco S, Mitchell N. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rheum Dis. 2016;75(6):1081–1091. doi: 10.1136/ annrheumdis-2015-207628Kaneko Y, Atsumi T, Tanaka Y, Inoo M, Kobayashi-Haraoka H, et al. Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). Ann Rheum Dis. 2016;75(11):1917–1923. doi: 10.1136/annrheumdis-2015-208426Kaneko Y, Atsumi T, Tanaka Y, Inoo M, Kobayashi-Haraoka H, et al. Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). Ann Rheum Dis. 2016;75(11):1917–1923. doi: 10.1136/annrheumdis-2015-208426Teitsma XM, Marijnissen AK, Bijlsma JW, Lafeber FP, Jacobs JW. Tocilizumab as monotherapy or combination therapy for treating active rheumatoid arthritis: a meta-analysis of efficacy and safety reported in randomized controlled trials. Arthritis Res Ther. 2016;18(1):211. doi: 10.1186/s13075-016-1108-9Teitsma XM, Marijnissen AK, Bijlsma JW, Lafeber FP, Jacobs JW. Tocilizumab as monotherapy or combination therapy for treating active rheumatoid arthritis: a meta-analysis of efficacy and safety reported in randomized controlled trials. Arthritis Res Ther. 2016;18(1):211. doi: 10.1186/s13075-016-1108-9Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, et al. Baricitinib in Patients with Refractory Rheumatoid Arthritis. N Engl J Med. 2016;374(13):1243-52. doi: 10.1056/NEJMoa1507247Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, et al. Baricitinib in Patients with Refractory Rheumatoid Arthritis. N Engl J Med. 2016;374(13):1243-52. doi: 10.1056/NEJMoa1507247Насонов ЕЛ, Коротаева ТВ. Ингибиторы Янус-киназ при иммуновоспалительных заболеваниях: 10 лет клинической практики в ревматологии. Научно-практическая ревматология. 2022;60(2):131-148.Nasonov EL, Korotaeva TV. Janus kinase inhibitors in immunoinflammatory diseases: 10 years of clinical practice in rheumatology. Nauchno-Prakticheskaya Rev matologia = Rheumatology Science and Practice. 2022;60(2):131–148 (In Russ.). doi: 10.47360/1995-4484-2022-131-148Aletaha D, Smolen JS. Remission in rheumatoid arthritis: missing objectives by using inadequate DAS28 targets. Nat Rev Rheumatol. 2019;15(11):633–634. doi: 10.1038/s41584-019-0279-6Aletaha D, Smolen JS. Remission in rheumatoid arthritis: missing objectives by using inadequate DAS28 targets. Nat Rev Rheumatol. 2019;15(11):633–634. doi: 10.1038/s41584-019-0279-6Felson DT, Lacaille D, LaValley MP, Aletaha D. Reexamining Remission Definitions in Rheumatoid Arthritis: Considering Disease Activity Score in 28 Joints, C-Reactive Protein, and Patient Global Assessment. ACR Open Rheumatol. 2022;4(2):123–127. doi: 10.1002/acr2.11345Felson DT, Lacaille D, LaValley MP, Aletaha D. Reexamining Remission Definitions in Rheumatoid Arthritis: Considering Disease Activity Score in 28 Joints, C-Reactive Protein, and Patient Global Assessment. ACR Open Rheumatol. 2022;4(2):123–127. doi: 10.1002/acr2.11345Lauper K, Iudici M, Mongin D, Bergstra SA, Choquette D, et al. Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration. Ann Rheum Dis. 2022 Jun 15. doi: 10.1136/annrheumdis-2022-222586Lauper K, Iudici M, Mongin D, Bergstra SA, Choquette D, et al. Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration. Ann Rheum Dis. 2022 Jun 15. doi: 10.1136/annrheumdis-2022-222586Shimamoto K, Ito T, Ozaki Y, Amuro H, Tanaka A, et al. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis. J Rheumatol. 2013;40(7):1074–1081. doi: 10.3899/jrheum.121389Shimamoto K, Ito T, Ozaki Y, Amuro H, Tanaka A, et al. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis. J Rheumatol. 2013;40(7):1074–1081. doi: 10.3899/jrheum.121389Nishimoto N, Amano K, Hirabayashi Y, Horiuchi T, Ishii T, et al. Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study. Mod Rheumatol. 2014;24(1):17–25. doi: 10.3109/14397595.2013.854079Nishimoto N, Amano K, Hirabayashi Y, Horiuchi T, Ishii T, et al. Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study. Mod Rheumatol. 2014;24(1):17–25. doi: 10.3109/14397595.2013.854079Shafran IH, Alasti F, Smolen JS, Aletaha D. Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab. Ann Rheum Dis. 2020;79(7):874–882. doi: 10.1136/annrheumdis-2019-215987Shafran IH, Alasti F, Smolen JS, Aletaha D. Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab. Ann Rheum Dis. 2020;79(7):874–882. doi: 10.1136/annrheumdis-2019-215987Boyapati A, Schwartzman S, Msihid J, Choy E, Genovese MC, et al. Association of High Serum Interleukin-6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc Analysis. Arthritis Rheumatol. 2020;72(9):1456–1466. doi: 10.1002/art.41299Boyapati A, Schwartzman S, Msihid J, Choy E, Genovese MC, et al. Association of High Serum Interleukin-6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc Analysis. Arthritis Rheumatol. 2020;72(9):1456–1466. doi: 10.1002/art.41299Gardette A, Ottaviani S, Sellam J, Berenbaum F, Lioté F, et al. Body mass index and response to tocilizumab in rheumatoid arthritis: a real life study. Clin Rheumatol. 2016;35(4):857–861. doi: 10.1007/s10067-016-3183-3Gardette A, Ottaviani S, Sellam J, Berenbaum F, Lioté F, et al. Body mass index and response to tocilizumab in rheumatoid arthritis: a real life study. Clin Rheumatol. 2016;35(4):857–861. doi: 10.1007/s10067-016-3183-3Davies R, Vivekanantham A, Lunt M, et al. The effect of bodyweight on response to intravenous or subcutaneous tocilizumab in patients with rheumatoid arthritis. Ann Rheum Dis. 2020;79:981. doi:10.1136/annrheumdis-2020-eular.4164Davies R, Vivekanantham A, Lunt M, et al. The effect of bodyweight on response to intravenous or subcutaneous tocilizumab in patients with rheumatoid arthritis. Ann Rheum Dis. 2020;79:981. doi:10.1136/annrheumdis-2020-eular.4164Nouri B, Nair N, Barton A. Predicting treatment response to IL6R blockers in rheumatoid arthritis. Rheumatology (Oxford). 2020;59(12):3603–3610. doi: 10.1093/rheumatology/keaa529Nouri B, Nair N, Barton A. Predicting treatment response to IL6R blockers in rheumatoid arthritis. Rheumatology (Oxford). 2020;59(12):3603–3610. doi: 10.1093/rheumatology/keaa529Burmester GR, Buttgereit F, Bernasconi C, Álvaro-Gracia JM, Castro N, et al.; SEMIRA collaborators. Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial. Lancet. 2020;396(10246):267–276. doi: 10.1016/S0140-6736(20)30636-XBurmester GR, Buttgereit F, Bernasconi C, Álvaro-Gracia JM, Castro N, et al.; SEMIRA collaborators. Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial. Lancet. 2020;396(10246):267–276. doi: 10.1016/S0140-6736(20)30636-XCrnkic Kapetanovic M, Saxne T, Truedsson L, Geborek P. Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugs. Arthritis Res Ther. 2013;15(1):R1. doi: 10.1186/ar4127Crnkic Kapetanovic M, Saxne T, Truedsson L, Geborek P. Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugs. Arthritis Res Ther. 2013;15(1):R1. doi: 10.1186/ar4127Mori S, Ueki Y, Akeda Y, Hirakata N, Oribe M, Shiohira Y, Hidaka T, Oishi K. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy. Ann Rheum Dis. 2013;72(8):1362–1366. doi: 10.1136/annrheumdis-2012-202658Mori S, Ueki Y, Akeda Y, Hirakata N, Oribe M, Shiohira Y, Hidaka T, Oishi K. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy. Ann Rheum Dis. 2013;72(8):1362–1366. doi: 10.1136/annrheumdis-2012-202658Bingham CO 3rd, Rizzo W, Kivitz A, Hassanali A, Upmanyu R, Klearman M. Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA). Ann Rheum Dis. 2015;74(5):818–822. doi: 10.1136/annrheumdis-2013-204427Bingham CO 3rd, Rizzo W, Kivitz A, Hassanali A, Upmanyu R, Klearman M. Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA). Ann Rheum Dis. 2015;74(5):818–822. doi: 10.1136/annrheumdis-2013-204427Alunno A, Najm A, Machado PM, Bertheussen H, Burmester GR, et al. EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19. Ann Rheum Dis. 2021;80(6):698–706. doi: 10.1136/annrheumdis-2020-219724Alunno A, Najm A, Machado PM, Bertheussen H, Burmester GR, et al. EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19. Ann Rheum Dis. 2021;80(6):698–706. doi: 10.1136/annrheumdis-2020-219724Rutherford AI, Patarata E, Subesinghe S, Hyrich KL, Galloway JB. Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology (Oxford). 2018;57(6):997–1001. doi: 10.1093/ rheumatology/key023.Rutherford AI, Patarata E, Subesinghe S, Hyrich KL, Galloway JB. Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology (Oxford). 2018;57(6):997–1001. doi: 10.1093/ rheumatology/key023.Curtis JR, Xie F, Yun H, Bernatsky S, Winthrop KL. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75(10):1843–1847. doi: 10.1136/annrheumdis-2016-209131Curtis JR, Xie F, Yun H, Bernatsky S, Winthrop KL. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75(10):1843–1847. doi: 10.1136/annrheumdis-2016-209131Souto A, Maneiro JR, Salgado E, Carmona L, Gomez-Reino JJ. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. Rheumatology (Oxford). 2014;53(10):1872–1885. doi: 10.1093/rheumatology/keu172Souto A, Maneiro JR, Salgado E, Carmona L, Gomez-Reino JJ. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. Rheumatology (Oxford). 2014;53(10):1872–1885. doi: 10.1093/rheumatology/keu172Wadström H, Frisell T, Askling J; Anti-Rheumatic Therapy in Swe den (ARTIS) Study Group. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden. JAMA Intern Med. 2017;177(11):1605–1612. doi: 10.1001/jamainternmed.2017.4332Wadström H, Frisell T, Askling J; Anti-Rheumatic Therapy in Swe den (ARTIS) Study Group. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden. JAMA Intern Med. 2017;177(11):1605–1612. doi: 10.1001/jamainternmed.2017.4332Harigai M, Nanki T, Koike R, Tanaka M, Watanabe-Imai K, et al. Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: A nationwide cohort study in Japan. Mod Rheumatol. 2016;26(5):642–650. doi: 10.3109/14397595.2016.1141740.Harigai M, Nanki T, Koike R, Tanaka M, Watanabe-Imai K, et al. Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: A nationwide cohort study in Japan. Mod Rheumatol. 2016;26(5):642–650. doi: 10.3109/14397595.2016.1141740.Strangfeld A, Richter A, Siegmund B, Herzer P, Rockwitz K, et al. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs. Ann Rheum Dis. 2017;76(3):504–510. doi: 10.1136/annrheumdis-2016-209773Strangfeld A, Richter A, Siegmund B, Herzer P, Rockwitz K, et al. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs. Ann Rheum Dis. 2017;76(3):504–510. doi: 10.1136/annrheumdis-2016-209773Bulte JP, Postma N, Beukema M, Inberg B, Stegeman AG, van der Hoeven H. COVID 19 and the risk of gastro-intestinal perforation: A case series and literature review. J Crit Care. 2022;67:100– 103. doi: 10.1016/j.jcrc.2021.10.020Bulte JP, Postma N, Beukema M, Inberg B, Stegeman AG, van der Hoeven H. COVID 19 and the risk of gastro-intestinal perforation: A case series and literature review. J Crit Care. 2022;67:100– 103. doi: 10.1016/j.jcrc.2021.10.020Genovese MC, Kremer JM, van Vollenhoven RF, Alten R, Scali JJ, еt al. Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid Arthritis. Arthritis Rheumatol. 2017;69(9):1751–1761. doi: 10.1002/art.40176Genovese MC, Kremer JM, van Vollenhoven RF, Alten R, Scali JJ, еt al. Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid Arthritis. Arthritis Rheumatol. 2017;69(9):1751–1761. doi: 10.1002/art.40176McInnes IB, Thompson L, Giles JT, Bathon JM, Salmon JE, et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis. 2015;74(4):694-702 doi: 10.1136/annrheumdis-2013-204345McInnes IB, Thompson L, Giles JT, Bathon JM, Salmon JE, et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis. 2015;74(4):694-702 doi: 10.1136/annrheumdis-2013-204345Gabay C, McInnes IB, Kavanaugh A, Tuckwell K, Klearman M, et al. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75(10): 1806–1812. doi: 10.1136/annrheumdis-2015-207872Gabay C, McInnes IB, Kavanaugh A, Tuckwell K, Klearman M, et al. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75(10): 1806–1812. doi: 10.1136/annrheumdis-2015-207872Giles JT, Sattar N, Gabriel S, Ridker PM, Gay S, et al. Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial. Arthritis Rheumatol. 2020;72(1):31–40. doi: 10.1002/art.41095Giles JT, Sattar N, Gabriel S, Ridker PM, Gay S, et al. Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial. Arthritis Rheumatol. 2020;72(1):31–40. doi: 10.1002/art.41095Kim SC, Solomon DH, Rogers JR, Gale S, Klearman M, Sarsour K, Schneeweiss S. Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study. Arthritis Rheumatol. 2017;69(6):1154–1164. doi: 10.1002/art.40084Kim SC, Solomon DH, Rogers JR, Gale S, Klearman M, Sarsour K, Schneeweiss S. Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study. Arthritis Rheumatol. 2017;69(6):1154–1164. doi: 10.1002/art.40084Kim SC, Solomon DH, Rogers JR, Gale S, Klearman M, Sarsour K, Schneeweiss S. No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: A multi-database cohort study. Semin Arthritis Rheum. 2018;48(3):399–405. doi: 10.1016/j.semarthrit.2018.03.012Kim SC, Solomon DH, Rogers JR, Gale S, Klearman M, Sarsour K, Schneeweiss S. No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: A multi-database cohort study. Semin Arthritis Rheum. 2018;48(3):399–405. doi: 10.1016/j.semarthrit.2018.03.012Xie F, Yun H, Levitan EB, Muntner P, Curtis JR. Tocilizumab and the Risk of Cardiovascular Disease: Direct Comparison Among Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Patients. Arthritis Care Res (Hoboken). 2019;71(8):1004–1018. doi: 10.1002/acr.23737Xie F, Yun H, Levitan EB, Muntner P, Curtis JR. Tocilizumab and the Risk of Cardiovascular Disease: Direct Comparison Among Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Patients. Arthritis Care Res (Hoboken). 2019;71(8):1004–1018. doi: 10.1002/acr.23737Tyrrell DJ, Goldstein DR. Ageing and atherosclerosis: vascular intrinsic and extrinsic factors and potential role of IL-6. Nat Rev Cardiol. 2021;18(1):58-68. doi: 10.1038/s41569-020-0431-7Tyrrell DJ, Goldstein DR. Ageing and atherosclerosis: vascular intrinsic and extrinsic factors and potential role of IL-6. Nat Rev Cardiol. 2021;18(1):58-68. doi: 10.1038/s41569-020-0431-7Feng Y, Ye D, Wang Z, Pan H, Lu X, Wang M, Xu Y, Yu J, Zhang J, Zhao M, Xu S, Pan W, Yin Z, Ye J, Wan J. The Role of Interleukin-6 Family Members in Cardiovascular Diseases. Front Cardiovasc Med. 2022;9:818890. doi: 10.3389/fcvm.2022.818890Feng Y, Ye D, Wang Z, Pan H, Lu X, Wang M, Xu Y, Yu J, Zhang J, Zhao M, Xu S, Pan W, Yin Z, Ye J, Wan J. The Role of Interleukin-6 Family Members in Cardiovascular Diseases. Front Cardiovasc Med. 2022;9:818890. doi: 10.3389/fcvm.2022.818890Ridker PM, Rane M. Interleukin-6 Signaling and AntiInterleukin-6 Therapeutics in Cardiovascular Disease. Circ Res. 2021;128(11):1728–1746. doi: 10.1161/CIRCRESAHA.121.319077Ridker PM, Rane M. Interleukin-6 Signaling and AntiInterleukin-6 Therapeutics in Cardiovascular Disease. Circ Res. 2021;128(11):1728–1746. doi: 10.1161/CIRCRESAHA.121.319077Huse C, Anstensrud AK, Michelsen AE, Ueland T, Broch K, et al. Interleukin-6 inhibition in ST-elevation myocardial infarction: Immune cell profile in the randomised ASSAIL-MI trial. EBioMedicine. 2022;80:104013. doi: 10.1016/j.ebiom.2022.104013Huse C, Anstensrud AK, Michelsen AE, Ueland T, Broch K, et al. Interleukin-6 inhibition in ST-elevation myocardial infarction: Immune cell profile in the randomised ASSAIL-MI trial. EBioMedicine. 2022;80:104013. doi: 10.1016/j.ebiom.2022.104013Ridker PM, Devalaraja M, Baeres FMM, Engelmann MDM, Hovingh GK, et al.; RESCUE Investigators. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021;397(10289):2060–2069. doi: 10.1016/S0140- 6736(21)00520-1Ridker PM, Devalaraja M, Baeres FMM, Engelmann MDM, Hovingh GK, et al.; RESCUE Investigators. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021;397(10289):2060–2069. doi: 10.1016/S0140- 6736(21)00520-1Paul SK, Montvida O, Best JH, Gale S, Pethoe-Schramm A, Sarsour K. Effectiveness of biologic and non-biologic antirheumatic drugs on anaemia markers in 153,788 patients with rheumatoid arthritis: New evidence from real-world data. Semin Arthritis Rheum. 2018;47(4):478–484. doi: 10.1016/j.semarthrit.2017.08.001Paul SK, Montvida O, Best JH, Gale S, Pethoe-Schramm A, Sarsour K. Effectiveness of biologic and non-biologic antirheumatic drugs on anaemia markers in 153,788 patients with rheumatoid arthritis: New evidence from real-world data. Semin Arthritis Rheum. 2018;47(4):478–484. doi: 10.1016/j.semarthrit.2017.08.001Moots RJ, Sebba A, Rigby W, Ostor A, Porter-Brown B, et al. Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials. Rheumatology (Oxford). 2017;56(4):541–549. doi: 10.1093/rheumatology/kew370Moots RJ, Sebba A, Rigby W, Ostor A, Porter-Brown B, et al. Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials. Rheumatology (Oxford). 2017;56(4):541–549. doi: 10.1093/rheumatology/kew370Chen SK, Lee H, Jin Y, Liu J, Kim SC. Use of biologic or targeted-synthetic disease-modifying anti-rheumatic drugs and risk of diabetes treatment intensification in patients with rheumatoid arthritis and diabetes mellitus. Rheumatol Adv Pract. 2020;4(2):rkaa027. doi: 10.1093/rap/rkaa027Chen SK, Lee H, Jin Y, Liu J, Kim SC. Use of biologic or targeted-synthetic disease-modifying anti-rheumatic drugs and risk of diabetes treatment intensification in patients with rheumatoid arthritis and diabetes mellitus. Rheumatol Adv Pract. 2020;4(2):rkaa027. doi: 10.1093/rap/rkaa027Genovese MC, Burmester GR, Hagino O, Thangavelu K, Iglesias-Rodriguez M, et al. Interleukin-6 receptor blockade or TNFα inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials. Arthritis Res Ther. 2020;22(1):206. doi: 10.1186/s13075- 020-02229-5Genovese MC, Burmester GR, Hagino O, Thangavelu K, Iglesias-Rodriguez M, et al. Interleukin-6 receptor blockade or TNFα inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials. Arthritis Res Ther. 2020;22(1):206. doi: 10.1186/s13075- 020-02229-5Otsuka Y, Kiyohara C, Kashiwado Y, Sawabe T, Nagano S, et al.. Effects of tumor necrosis factor inhibitors and tocilizumab on the glycosylated hemoglobin levels in patients with rheumatoid arthritis; an observational study. PLoS One. 2018;13(4):e0196368. doi: 10.1371/journal.pone.0196368Otsuka Y, Kiyohara C, Kashiwado Y, Sawabe T, Nagano S, et al.. Effects of tumor necrosis factor inhibitors and tocilizumab on the glycosylated hemoglobin levels in patients with rheumatoid arthritis; an observational study. PLoS One. 2018;13(4):e0196368. doi: 10.1371/journal.pone.0196368Mori S, Yoshitama T, Hidaka T, Hirakata N, Ueki Y. Effectiveness and safety of tocilizumab therapy for patients with rheumatoid arthritis and renal insufficiency: a real-life registry study in Japan (the ACTRA-RI study). Ann Rheum Dis. 2015;74(3):627–630. doi: 10.1136/annrheumdis-2014-206695Mori S, Yoshitama T, Hidaka T, Hirakata N, Ueki Y. Effectiveness and safety of tocilizumab therapy for patients with rheumatoid arthritis and renal insufficiency: a real-life registry study in Japan (the ACTRA-RI study). Ann Rheum Dis. 2015;74(3):627–630. doi: 10.1136/annrheumdis-2014-206695Okuda Y. AA amyloidosis – Benefits and prospects of IL-6 inhibitors. Mod Rheumatol. 2019;29(2):268–274. doi: 10.1080/14397595.2018.1515145Okuda Y. AA amyloidosis – Benefits and prospects of IL-6 inhibitors. Mod Rheumatol. 2019;29(2):268–274. doi: 10.1080/14397595.2018.1515145Jung JY, Kim YB, Kim JW, Suh CH, Kim HA. Biologic therapy for amyloid A amyloidosis secondary to rheumatoid arthritis treated with interleukin 6 therapy: Case report and review of literature. Medicine (Baltimore). 2021;100(32):e26843. doi: 10.1097/ MD.0000000000026843Jung JY, Kim YB, Kim JW, Suh CH, Kim HA. Biologic therapy for amyloid A amyloidosis secondary to rheumatoid arthritis treated with interleukin 6 therapy: Case report and review of literature. Medicine (Baltimore). 2021;100(32):e26843. doi: 10.1097/ MD.0000000000026843Curtis JR, Sarsour K, Napalkov P, Costa LA, Schulman KL. Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor α agents, a retrospective cohort study. Arthritis Res Ther. 2015;17:319. doi: 10.1186/s13075-015-0835-7Curtis JR, Sarsour K, Napalkov P, Costa LA, Schulman KL. Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor α agents, a retrospective cohort study. Arthritis Res Ther. 2015;17:319. doi: 10.1186/s13075-015-0835-7Strangfeld A, Meissner Y, Schäfer BL. No confirmation of increased risk of idiopathic facial nerve palsy under tocilizumab. Arthritis Rheumatol. 2019;71:2306–2308.Strangfeld A, Meissner Y, Schäfer BL. No confirmation of increased risk of idiopathic facial nerve palsy under tocilizumab. Arthritis Rheumatol. 2019;71:2306–2308.Khanna D, Lin CJF, Furst DE, Goldin J, Kim G, et al.; focuSSced investigators. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2020;8(10):963–974. doi: 10.1016/S2213-2600(20)30318-0Khanna D, Lin CJF, Furst DE, Goldin J, Kim G, et al.; focuSSced investigators. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2020;8(10):963–974. doi: 10.1016/S2213-2600(20)30318-0Roofeh D, Lin CJF, Goldin J, Kim GH, Furst DE, et al.; focuSSced Investigators. Tocilizumab Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung Disease. Arthritis Rheumatol. 2021;73(7):1301–1310. doi: 10.1002/art.41668Roofeh D, Lin CJF, Goldin J, Kim GH, Furst DE, et al.; focuSSced Investigators. Tocilizumab Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung Disease. Arthritis Rheumatol. 2021;73(7):1301–1310. doi: 10.1002/art.41668Zhang C, Zhang M, Qiu W, Ma H, Zhang X, et al.; TANGO Study Investigators. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol. 2020;19(5):391-401. doi: 10.1016/S1474-4422(20)30070-3Zhang C, Zhang M, Qiu W, Ma H, Zhang X, et al.; TANGO Study Investigators. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol. 2020;19(5):391-401. doi: 10.1016/S1474-4422(20)30070-3Shin A, Park EH, Dong YH, Ha YJ, Lee YJ, et al. Comparative risk of osteoporotic fracture among patients with rheumatoid arthritis receiving TNF inhibitors versus other biologics: a cohort study. Osteoporos Int. 2020;31(11):2131–2139. doi: 10.1007/s00198- 020-05488-9Shin A, Park EH, Dong YH, Ha YJ, Lee YJ, et al. Comparative risk of osteoporotic fracture among patients with rheumatoid arthritis receiving TNF inhibitors versus other biologics: a cohort study. Osteoporos Int. 2020;31(11):2131–2139. doi: 10.1007/s00198- 020-05488-9Kume K, Amano K, Yamada S, Kanazawa T, Ohta H, et al. The effect of tocilizumab on bone mineral density in patients with methotrexate-resistant active rheumatoid arthritis. Rheumatology (Oxford). 2014;53(5):900–903. doi: 10.1093/rheumatology/ket468Kume K, Amano K, Yamada S, Kanazawa T, Ohta H, et al. The effect of tocilizumab on bone mineral density in patients with methotrexate-resistant active rheumatoid arthritis. Rheumatology (Oxford). 2014;53(5):900–903. doi: 10.1093/rheumatology/ket468Chen YM, Chen HH, Huang WN, Liao TL, Chen JP, et al. Tocilizumab potentially prevents bone loss in patients with anticitrullinated protein antibody-positive rheumatoid arthritis. PLoS One. 2017;12(11):e0188454. doi: 10.1371/journal. pone.0188454Chen YM, Chen HH, Huang WN, Liao TL, Chen JP, et al. Tocilizumab potentially prevents bone loss in patients with anticitrullinated protein antibody-positive rheumatoid arthritis. PLoS One. 2017;12(11):e0188454. doi: 10.1371/journal. pone.0188454Yun H, Xie F, Beyl RN, Chen L, Lewis JD, et al. Risk of Hypersensitivity to Biologic Agents Among Medicare Patients With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2017;69(10):1526–1534. doi: 10.1002/acr.23141Yun H, Xie F, Beyl RN, Chen L, Lewis JD, et al. Risk of Hypersensitivity to Biologic Agents Among Medicare Patients With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2017;69(10):1526–1534. doi: 10.1002/acr.23141Burmester GR, Choy E, Kivitz A, Ogata A, Bao M, et al.. Low immunogenicity of tocilizumab in patients with rheumatoid arthritis. Ann Rheum Dis. 2017;76(6):1078–1085. doi: 10.1136/ annrheumdis-2016-210297Burmester GR, Choy E, Kivitz A, Ogata A, Bao M, et al.. Low immunogenicity of tocilizumab in patients with rheumatoid arthritis. Ann Rheum Dis. 2017;76(6):1078–1085. doi: 10.1136/ annrheumdis-2016-210297Nasonov E, Samsonov M. The role of Interleukin 6 inhibitors in therapy of severe COVID-19. Biomed Pharmacother. 2020;131:110698. doi: 10.1016/j.biopha.2020.110698Nasonov E, Samsonov M. The role of Interleukin 6 inhibitors in therapy of severe COVID-19. Biomed Pharmacother. 2020;131:110698. doi: 10.1016/j.biopha.2020.110698McElvaney OJ, Curley GF, Rose-John S, McElvaney NG. Interleukin-6: obstacles to targeting a complex cytokine in critical illness. Lancet Respir Med. 2021;9(6):643–654. doi: 10.1016/ S2213-2600(21)00103-XMcElvaney OJ, Curley GF, Rose-John S, McElvaney NG. Interleukin-6: obstacles to targeting a complex cytokine in critical illness. Lancet Respir Med. 2021;9(6):643–654. doi: 10.1016/ S2213-2600(21)00103-Xvan de Veerdonk FL, Giamarellos-Bourboulis E, Pickkers P, Derde L, Leavis H, et al. A guide to immunotherapy for COVID-19. Nat Med. 2022;28(1):39–50. doi: 10.1038/ s41591-021-01643-9van de Veerdonk FL, Giamarellos-Bourboulis E, Pickkers P, Derde L, Leavis H, et al. A guide to immunotherapy for COVID-19. Nat Med. 2022;28(1):39–50. doi: 10.1038/ s41591-021-01643-9Antonov VN, Ignatova GL, Pribytkova OV, Sleptsova SS, Strebkova EA, et al. [Experience of olokizumab use in COVID-19 patients]. Ter Arkh. 2020;92(12):148–154. Russian. doi: 10.26442/00403660.2 020.12.200522Antonov VN, Ignatova GL, Pribytkova OV, Sleptsova SS, Strebkova EA, et al. [Experience of olokizumab use in COVID-19 patients]. Ter Arkh. 2020;92(12):148–154. Russian. doi: 10.26442/00403660.2 020.12.200522Бобкова СС, Жуков ФФ, Проценко ДН, Самойленко ВВ, Тюрин ИН. Сравнительная эффективность и безопасность применения препаратов моноклональных антитед к ИЛ-6 у пациентов с новой коронавирусной инфекцией тяжелого течения. Ретроспективное когортное исследование. Вестник интенсивной терапии им. А.И. Салтанова. 2021;1:69–76. doi:10.21320/1818-474X-2021-1-69-76Kang S, Narazaki M, Metwally H, Kishimoto T. Historical overview of the interleukin-6 family cytokine. J Exp Med. 2020;217(5):e20190347. doi: 10.1084/jem.20190347.Kang S, Narazaki M, Metwally H, Kishimoto T. Historical overview of the interleukin-6 family cytokine. J Exp Med. 2020;217(5):e20190347. doi: 10.1084/jem.20190347.Gordeev AV, Galushko EA, Nasonov EL. The concept of multi-morbidity in rheumatologic practice. Nauchno-Prakticheskaya Rev matologia = Rheumatology Science and Practice. 2014;52(4):362–365 (In Russ.)]. doi: 10.14412/1995-4484-2014-362-365Гордеев АВ, Галушко ЕА, Насонов ЕЛ. Концепция мультиморбидности в ревматологической практике. Научнопрактическая ревматология. 2014;52(4):362-365.Taylor PC, Atzeni F, Balsa A, Gossec L, Müller-Ladner U, Pope J. The Key Comorbidities in Patients with Rheumatoid Arthritis: A Narrative Review. J Clin Med. 2021;10(3):509. doi: 10.3390/ jcm10030509Taylor PC, Atzeni F, Balsa A, Gossec L, Müller-Ladner U, Pope J. The Key Comorbidities in Patients with Rheumatoid Arthritis: A Narrative Review. J Clin Med. 2021;10(3):509. doi: 10.3390/ jcm10030509Hill J, Harrison J, Christian D, Reed J, Clegg A, Duffield SJ, Goodson N, Marson T. The prevalence of comorbidity in rheumatoid arthritis: a systematic review and meta-analysis. Br J Community Nurs. 2022;27(5):232–241. doi: 10.12968/bjcn.2022.27.5.232Hill J, Harrison J, Christian D, Reed J, Clegg A, Duffield SJ, Goodson N, Marson T. The prevalence of comorbidity in rheumatoid arthritis: a systematic review and meta-analysis. Br J Community Nurs. 2022;27(5):232–241. doi: 10.12968/bjcn.2022.27.5.232Ting EY, Yang AC, Tsai SJ. Role of Interleukin-6 in Depressive Disorder. Int J Mol Sci. 2020 Mar 22;21(6):2194. doi: 10.3390/ ijms21062194Ting EY, Yang AC, Tsai SJ. Role of Interleukin-6 in Depressive Disorder. Int J Mol Sci. 2020 Mar 22;21(6):2194. doi: 10.3390/ ijms21062194Lisitsyna TA, Veltishchev DYu, Lila AM, Nasonov EL. Interleukin 6 as a pathogenic factor mediating clinical manifestations and a therapeutic target for rheumatic diseases and depressive disorders. Nauchno-Prakticheskaya Rev matologia = Rheumatology Science and Practice. 2019;57(3):318–327 (In Russ.). doi: org/10.14412/ 1995-4484-2019-318-327Лисицына ТА, Вельтищев ДЮ, Лила АМ, Насонов ЕЛ. Интерлейкин-6 как патогенетический фактор, опосредующий формирование клинических проявлений, и мишень для терапии ревматических заболеваний и депрессивных расстройств. Научно-практическая ревматология. 2019;57(3):318–327.Roohi E, Jaafari N, Hashemian F. On inflammatory hypothesis of depression: what is the role of IL-6 in the middle of the chaos? J Neuroinflammation. 2021;18(1):45. doi: 10.1186/s12974-021- 02100-7Roohi E, Jaafari N, Hashemian F. On inflammatory hypothesis of depression: what is the role of IL-6 in the middle of the chaos? J Neuroinflammation. 2021;18(1):45. doi: 10.1186/s12974-021- 02100-7Sebba A. Pain: A Review of Interleukin-6 and Its Roles in the Pain of Rheumatoid Arthritis. Open Access Rheumatol. 2021;13:31–43. doi: 10.2147/OARRR.S291388Sebba A. Pain: A Review of Interleukin-6 and Its Roles in the Pain of Rheumatoid Arthritis. Open Access Rheumatol. 2021;13:31–43. doi: 10.2147/OARRR.S291388Antonio AA, Santos RN, Abariga SA. Tocilizumab for giant cell arteritis. Cochrane Database Syst Rev. 2021;8(8):CD013484. doi: 10.1002/14651858.CD013484.pub2. Update in: Cochrane Database Syst Rev. 2022;5:CD013484.Antonio AA, Santos RN, Abariga SA. Tocilizumab for giant cell arteritis. Cochrane Database Syst Rev. 2021;8(8):CD013484. doi: 10.1002/14651858.CD013484.pub2. Update in: Cochrane Database Syst Rev. 2022;5:CD013484.Conway R, Putman MS, Mackie SL. Benchmarking tocilizumab use for giant cell arteritis. Rheumatol Adv Pract. 2022;6(2):rkac037. doi: 10.1093/rap/rkac037Conway R, Putman MS, Mackie SL. Benchmarking tocilizumab use for giant cell arteritis. Rheumatol Adv Pract. 2022;6(2):rkac037. doi: 10.1093/rap/rkac037Beketova TV, Ushakova MA, Nikishina NYu, Khelkovskaya-Sergeeva AN, Nikolaeva EV, et al. Experience with tocilizumab, an interleukin 6 inhibitor, used for the treatment of giant cell arteritis with severe comorbidity. Nauchno-Prakticheskaya Rev matologia = Rheumatology Science and Practice. 2018;56(2): 228–234 (In Russ.). doi: 10.14412/1995-4484-2018-228-234Бекетова ТВ, Ушакова МА, Никишина НЮ, ХелковскаяСергеева АН, Николаева ЕВ, и соавт. Опыт применения ингибитора интерлейкина-6 тоцилизумаба для лечения гигантоклеточного артериита с тяжелой коморбидной патологией. Научно-практическая ревматология. 2018;56(2):228– 234.Li H, Shuai Z. Efficacy of tocilizumab for refractory Takayasu arteritis: a retrospective study and literature review. Heart Vessels. 2022;37(5):884–894. doi: 10.1007/s00380-021-01981-1Li H, Shuai Z. Efficacy of tocilizumab for refractory Takayasu arteritis: a retrospective study and literature review. Heart Vessels. 2022;37(5):884–894. doi: 10.1007/s00380-021-01981-1Akioka S. Interleukin-6 in juvenile idiopathic arthritis. Mod Rheumatol. 2019;29(2):275–286. doi: 10.1080/14397595.2019. 1574697Akioka S. Interleukin-6 in juvenile idiopathic arthritis. Mod Rheumatol. 2019;29(2):275–286. doi: 10.1080/14397595.2019. 1574697Castañeda S, Martínez-Quintanilla D, Martín-Varillas JL, GarcíaCastañeda N, Atienza-Mateo B, et al. Tocilizumab for the treatment of adult-onset Still’s disease. Expert Opin Biol Ther. 2019;19(4):273–286. doi: 10.1080/14712598.2019.1590334Castañeda S, Martínez-Quintanilla D, Martín-Varillas JL, García-Castañeda N, Atienza-Mateo B, et al. Tocilizumab for the treatment of adult-onset Still’s disease. Expert Opin Biol Ther. 2019;19(4):273–286. doi: 10.1080/14712598.2019.1590334Koga T, Kawakami A. Interleukin-6 inhibition in the treatment of autoinflammatory diseases. Front Immunol. 2022;13:956795. doi: 10.3389/fimmu.2022.956795Koga T, Kawakami A. Interleukin-6 inhibition in the treatment of autoinflammatory diseases. Front Immunol. 2022;13:956795. doi: 10.3389/fimmu.2022.956795Si S, Teachey DT. Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date. Ther Clin Risk Manag. 2020;16:705–714. doi: 10.2147/TCRM.S223468Si S, Teachey DT. Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date. Ther Clin Risk Manag. 2020;16:705–714. doi: 10.2147/TCRM.S223468Zhang J, Luo W, Miao C, Zhong J. Hypercatabolism and Anticatabolic Therapies in the Persistent Inflammation, Immunosuppression, and Catabolism Syndrome. Front Nutr. 2022; 9:941097. doi: 10.3389/fnut.2022.941097Zhang J, Luo W, Miao C, Zhong J. Hypercatabolism and Anticatabolic Therapies in the Persistent Inflammation, Immunosuppression, and Catabolism Syndrome. Front Nutr. 2022; 9:941097. doi: 10.3389/fnut.2022.941097Zhang J, Luo W, Miao C, Zhong J. Hypercatabolism and Anticatabolic Therapies in the Persistent Inflammation, Immunosuppression, and Catabolism Syndrome. Front Nutr. 2022; 9:941097. doi: 10.3389/fnut.2022.941097

The authors declare that there are no conflicts of interest present.